Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

FDA approves TREANDA (bendamustine hydrochloride) for chronic lymphocytic leukemia

Cephalon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease, on March 20, 2008.

7 Apr 2008

Gene therapy protocol at UCSD activates immune system in patients with leukemia

A research team at the Moores Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells.

12 Feb 2008

Link between microRNA expression patterns and poor outcomes for colon cancer

Preliminary research has found an association between certain microRNA expression patterns and poor survival and treatment outcomes for colon cancer, according to a study in the January 30 issue of JAMA: The Journal of the American Medical Association.

30 Jan 2008

FDA extends review of Genasense NDA appeal in chronic lymphocytic leukemia

Genta Incorporated has announced that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

15 Jan 2008

Genmab announces HuMax-CD32b pre-clinical program

Genmab A/S has announced a new pre-clinical antibody program called HuMax-CD32b. This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors.

7 Jan 2008

Complete response with oblimersen combination improves survival of CLL patients

Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

10 Dec 2007

Ultraconserved non-coding RNAs may be important in human cancer

Research here shows that an obscure form of RNA, part of the protein-making machinery in all cells, might play an important role in human cancer.

12 Sep 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

New type of drug shows promise for chronic lymphocytic leukemia

A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

29 Jun 2007

Discovery of inherited gene mutation for leukemia

Researchers have discovered the first inherited gene mutation that increases a person's risk for chronic lymphocytic leukemia (CLL), one of the most common forms of the disease.

1 Jun 2007

Knocking out Mcl1 protein could aid leukemia treatment

An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows.

21 Apr 2007

Researchers induce cell death in leukemia

Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).

17 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007

Turning the immune system against cancer

Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.

4 Aug 2006

Roswell Park research aids development of myeloma drug

Roswell Park Cancer Institute (RPCI) researchers played a leading role in clinical studies which led to U.S. Food and Drug Administration (FDA) approval of a new treatment for patients diagnosed with multiple myeloma - the second most common blood cancer.

11 Jul 2006

Scientists identify microRNAs that appear to play a role in the development of platelets

Scientists have identified a handful of microRNAs (miRNAs) that appear to play a significant role in the development of platelets - blood cells critical to the body's ability to form clots following an injury.

21 Mar 2006

New and unusual class of genes plays an important role in the development of chronic lymphocytic leukemia

The study found that the loss of two genes for producing small molecules known as microRNAs enables damaged cells to survive, rather than normally self-destructing before they become cancerous.

12 Sep 2005

Experts on chronic lymphocytic leukemia (CLL) review current scientific knowledge

When the most common adult leukemia in the United States was last reviewed by the New England Journal of Medicine (NEJM) in 1995, it was seen through the eyes of theories that dated back to the 1960s.

24 Feb 2005

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).

13 Dec 2004

Obesity could more than double an older woman's risk of acute myelogenous leukemia

A study from the University of Minnesota Cancer Center indicates that overweight and obesity could more than double an older woman's risk of acute myelogenous leukemia (AML), an often fatal cancer of the bone marrow and blood.

8 Nov 2004